Biotech | November 12, 2021
Ronapreve gets the green light from CHMP to treat non-hospitalised Covid-19 patients
A final decision regarding the approval of Ronapreve is expected from the European Commission shortly
A final decision regarding the approval of Ronapreve is expected from the European Commission shortly
The implant is surgically inserted into the eye during a one-time, outpatient procedure and refilled every six months
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
If approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC
Roche is notifying healthcare professionals and patients in the US about this withdrawal. Patients being treated with Tecentriq for PD-L1-positive mTNBC should discuss their care with their healthcare provider
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)